Evolva Holding LTD
EVE
ISIN CH1262055788 / Valor 126205578
Evolva Holding LTD
UMushroom community rating:
About company
Evolva Holding Ltd is a Swiss biotechnology company that develops and commercializes ingredients for food, nutrition, health and consumer-product markets by applying synthetic biology and precision fermentation to produce specialty molecules that are difficult, costly or unsustainable to obtain from traditional sources. The company combines discovery and strain‑engineering with process development and scale‑up, then brings products to market through manufacturing partnerships, supply agreements and licensing to ingredient and brand customers. Its commercial focus is on high‑value, low‑volume compounds such as flavor and fragrance molecules and nutritional or bioactive ingredients, together with related contract manufacturing and regulatory pathways needed to support customer adoption.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (02.09.2026):
Evolva Holding LTD — reporting on the half‑year ended 30 June 2025 (covering Q1–Q2 2025, i.e., Q2 2025). The company (now renamed EvoNext Holdings Ltd) had no operating revenue after the sale of Evolva AG and posted an operating loss of CHF 367.3k and a net loss of CHF 361.2k for the period. Cash and equivalents stood at CHF 6.313m at 30 June 2025, total assets were CHF 7.085m and total equity was CHF 6.235m. Management notes a material uncertainty on going concern beyond 2025 and the earn‑out tied to the sale of Evolva AG did not pay out for 1H 2025.
Financial result
Operating loss of CHF 367.3k and net loss for the period of CHF 361.2k for the half‑year ended 30 June 2025; net financial result was positive CHF 6.1k (mainly interest income).
Revenue and operations
No revenue, cost of goods sold or R&D expense in 1H 2025 because the operating business (Evolva AG) was sold on 28 December 2023 and the company now has no operating activities.
Cash and liquidity
Cash and cash equivalents declined to CHF 6.313m at 30 June 2025 from CHF 6.753m at 1 January 2025; net cash flow from operating activities was negative CHF 440.3k for the period.
Balance sheet and equity
Total assets of CHF 7.085m and total equity of CHF 6.235m at 30 June 2025; accumulated loss increased to CHF (475.571m) on the balance sheet (note: amounts in thousands).
Provisions and contingencies
A provision of CHF 600k remains related to a potential price adjustment from the sale of Evolva AG; the company also disclosed a legal award in its favor (~CHF 88k) that was accrued and received in July 2025.
Earn‑out from sale of Evolva AG
An earn‑out agreement (maximum CHF 10m) linked to product sales was not triggered for 2024 and the sales floor for the second earn‑out period (Jan–Jun 2025) was also not met, so no earn‑out is expected for 1H 2025.
Corporate actions and going concern
The company’s name change to EvoNext Holdings Ltd was approved 25 July 2025. The board indicates the company may pursue reverse‑takeover or similar transactions, but states a material uncertainty exists regarding the ability to continue as a going concern beyond 2025 if no strategic or financing partner is found.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
21 M
Market cap (USD)
6,075
Daily traded volume (Shares)
0.896 / 0.8
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
D Y
Roger Schaad
EQUITIES OF THE SAME SECTOR
